Whilst the alternate donor site (AD) event in NFATC4 has been identified as a poor prognostic indicator for overall survival in gastric cancer [67], its association with overall survival appears to be the opposite in pancreatic cancer [68]. The gene discussed is NFATC4; the disease is gastric cancer.